Editas Medicine, Inc (NASDAQ:EDIT) Stock Forecast

sophia agwaonye
Ad disclosure WeInvests is an independent platform with the mission of simplifying financial decisions. Therefore, we work with independent professionals to offer you the latest news. We may receive compensation if you click on certain links, sponsored posts, products and/or services, transferring leads to brokers, or advertisements. We do our utmost best to ensure you will not incur any disadvantages as a user. No rights can be derived from the Content we provided on or through our website, nor should this be considered as legal, tax, investment, financial or other advice. The Content is for informational purposes only. In case of any doubt, you should seek advice from an independent financial advisor. Read More >>

This content represents the writer’s opinions and research and is not intended to be taken as financial advice. The information presented is general in nature and may not meet the specific needs of any individual or entity. It is not intended to be relied upon as a professional or financial decision-making tool.

Editas Medicine is a leading biotechnology company focused on developing novel genomic medicines using CRISPR/Cas9 gene editing technology. Their mission is to translate the promise of this groundbreaking technology into reality for patients with genetic diseases.

The company’s approach involves identifying and targeting specific disease-causing genes, then using CRISPR/Cas9 to edit them in a precise and targeted manner. This technology has the potential to provide a curative treatment for many genetic disorders that are currently untreatable or poorly managed by existing therapies.

Editas Medicine is focused on developing a pipeline of therapeutic candidates for a variety of genetic diseases, including inherited retinal diseases, sickle cell disease, and cancer. Their lead program, EDIT-101, is a gene therapy for a rare form of inherited blindness caused by mutations in the CEP290 gene. The therapy is currently in clinical trials and has shown promising results.

Editas Medicine has also formed collaborations with other leading biotechnology and pharmaceutical companies to advance the development of gene therapies and other genomic medicines. With a team of talented scientists and researchers, the company is at the forefront of the exciting field of gene editing and is poised to make a significant impact on the lives of people with genetic illness.

Editas Medicine Stock Forecast in 2023

Over the past three years, Editas Medicine shareholders have seen a significant drop in the value of their shares. Despite the company’s impressive gene-editing technology, the journey has been far from smooth for investors. However, the current share price should not be seen as a reflection of the company’s long-term potential as a leading gene-therapy developer.

If Editas Medicine can produce successful clinical trial results, it could boost investor confidence and generate positive attention for its innovative gene-editing technology. Nevertheless, there are reasons to believe that the company’s share price may not recover soon, despite its ongoing ambitions. To determine whether investing in Editas Medicine is a wise decision for the present and future, it’s essential to consider what the company has planned.

From our analysis, EDIT has been on a downtrend since 2021, losing more than 80% of its stock value per share. We forecast that EDIT will see lower prices in 2023 if nothing is done to attract investors. 

Editas Medicine Stock in 2022

In January 2022, Editas Medicine’s stock price decreased from $26 per share to $10 per share. The company had presented at the virtual J.P. Morgan Healthcare Conference and shared a generally positive outlook for its plans in 2022. However, the broader biotech sector experienced declines during that period, and Editas was not immune to this sell-off.

2022 daily chart EDIT 

Some investors may have been concerned that CRISPR base-editing therapies could become more popular than the CRISPR approach that Editas uses. During his comments at the conference, Editas Medicine CEO James Mullen mentioned base editing and appeared defensive about the topic. This may have added to investor worries about the company’s prospects.

In November 2022, Editas Medicine, a biotech company in the clinical development stage, saw a 15.5% decline in its stock price. In October 2022, the stock closed at $12.55 per share, but in November 2022, it began at $13 and continuously decreased throughout the month. It reached a low of $9.61 on November 17, which is very close to its previous low of $9.54.

This was the cause of the drop, Editas halted its phase 1/2 clinical trial of EDIT-101 for treating a rare genetic eye disease, Leber congenital amaurosis type 10 (LCA10), due to a small sample size of only 14 patients, of which only three showed progress, and only two had the mutation that responds best to the therapy. Although this is a significant setback, Editas will continue to research EDIT-101 for other uses. The company’s EDIT-301 is also in early-stage trials for treating genetic blood disorders, and Editas plans to provide an update on its phase 1/2 RUBY trial later.

Editas Medicine Stock in 2021

In April 2021, Editas Medicine was given a sell rating and a price target of $20 by Goldman Sachs analyst Madhu Kumar. At the time of the previous day’s market close, the stock was priced at $40.98. Despite a sell-off the following day, the stock remained at $34.21, still far above the predicted target price. This analyst caused a panic sell-off in April.

2021 daily chart EDIT 

In September 2021, Editas Medicine shared clinical data from its ongoing BRILLIANCE trial for EDIT-101, a treatment for Leber congenital amaurosis 10 (LCA10), a genetic disorder that causes blindness. The study involved four patients, and while investors were hoping for positive results across the board, only one patient showed “meaningful improvements,” and another was declared stable after the treatment. The small sample size of the trial left investors unsure about the efficacy of the gene-editing treatment compared to other options. The uncertainty from investors made the stock price crash.

Editas Medicine Stock in 2020

In the last quarter of 2020, EDIT went up over 200%, and this is why. Editas Medicine has been making significant strides in the development of its leading candidate, EDIT-101, which uses CRISPR gene editing to treat Leber congenital amaurosis type 10 (LCA10) – a rare genetic disease that causes blindness. This progress has resulted in a surge in the company’s stock price. 

2020 daily chart EDIT 

Editas has completed dosing in the first cohort of the phase I/II BRILLIANCE study evaluating EDIT-101 for LCA10, which has a significant unmet medical need as there is currently no approved therapy. In December 2020, Editas’ shares rose after the company announced preclinical data on EDIT-301 and the successful development of its large-scale manufacturing process. If EDIT-101 is successfully developed and approved, it would significantly boost the company’s growth prospects and drive the stock further.

Editas Medicine Stock in 2019

EDIT’s stock price was in a range in 2019 until the 4th quarter of the year, when it saw a substantial increase. Editas Medicine’s shares saw a significant increase in trading volume, even without any recent announcements. This rise could be due to the general market trend of small-cap stocks, as the Russell 2000 Index rose by over 2% on the same day. 

2019 daily chart EDIT 

Additionally, there was positive news regarding the use of CRISPR gene editing in treating eye diseases, which is the focus of Editas Medicine’s lead candidate, EDIT-101, targeting LCA10. It’s also possible that investors were anticipating positive news from the company’s participation in the Piper Jaffray Healthcare Conference and presentation at the American Society of Hematology annual meeting, where they planned to share pre-clinical data from their EDIT-301 program and move forward with their first clinical trial of EDIT-101 in early 2020.

Editas Medicine Stock in 2018

Editas Medicine experienced a 23% increase in November 2018. Editas Medicine has reported its third-quarter 2018 financial results, revealing a cash balance of $337 million as of September 30th. Additionally, the U.S. Food and Drug Administration has accepted the investigational new drug application for the company’s lead drug candidate, EDIT-101, which targets Leber congenital amaurosis type 10, a type of genetic eye disease.

2018 daily chart EDIT 

This acceptance will allow Editas Medicine to conduct a phase 1/2 trial evaluating the drug candidate’s safety in 10 to 20 patients, and it has also triggered a $25 million milestone payment from Allergan, the company’s partner in the development and commercialization of EDIT-101. If successful, this drug could pave the way for a promising pipeline of treatments for genetic diseases. This is the most likely catalyst for the increase in price experienced in November

Editas Medicine Stock in 2017

In May 2017, Editas Medicine’s stock fell by almost 16% after a new study was published in Nature Methods, which raised concerns about the CRISPR genetic engineering tool. The study, conducted by Columbia University Medical Center, revealed that CRISPR could create unintended mutations in the genome, contradicting the tool’s reputation for precision. As a result, investors are reevaluating the value of early-stage platforms, particularly Editas Medicine, which is set to enter clinical trials first. 

2017 daily chart EDIT 

In December 2017, Editas Medicine Inc., a biotech company that uses CRISPR technology to treat genetic diseases, saw a decline in its stock price after a secondary share offering was priced. The stock fell approximately 9.2%.


The past years have been a rollercoaster ride for Editas Medicine’s stock price, reflecting the ups and downs of the company’s progress in developing gene-editing treatments. The promising news of the FDA’s acceptance of the investigational new drug (IND) application for EDIT-101 in Leber congenital amaurosis type 10 (LCA10) provided some hope to investors, but the recent study showing unintended mutations caused by CRISPR technology has caused a setback in the stock’s performance.

Despite the uncertainty surrounding Editas Medicine’s future, it remains a pioneering company in gene-editing technology and could potentially transform the biotech industry if its approaches prove successful.


What caused the recent fluctuations in Editas Medicine’s stock prices ?

There have been various factors that caused the recent fluctuations in Editas Medicine’s stock prices, including positive announcements regarding the progress of their clinical trials and partnerships, as well as negative news such as a study highlighting the unintended effects of CRISPR technology.

Should I invest in Editas Medicine ?

Before making a choice, careful investigation and analysis are crucial, just as with any investment. Editas Medicine is a biotech company that aims to correct disease-causing genes with CRISPR technology, which has significant potential but also carries risks. Investors should evaluate Editas Medicine’s financial performance, pipeline, partnerships, and the market competition before investing.

Which online broker should I use to buy Editas Medicine stocks ?

There are various online brokers available, and the best one for you will depend on your preferences and needs. It has a user-friendly interface, innovative features, educational resources, and a community of traders to help users make informed investment decisions.

Risk Disclaimer

WeInvests is a financial portal-based research agency. We do our utmost best to offer reliable and unbiased information about crypto, finance, trading and stocks. However, we do not offer financial advice and users should always carry out their own research.

Read More